BR112014001665A2 - compostos de 2,3-di-hidroimidazo[1,2-c]pirimidin-5(1h)-ona utilizados como inibidores de lp-plaz - Google Patents
compostos de 2,3-di-hidroimidazo[1,2-c]pirimidin-5(1h)-ona utilizados como inibidores de lp-plazInfo
- Publication number
- BR112014001665A2 BR112014001665A2 BR112014001665A BR112014001665A BR112014001665A2 BR 112014001665 A2 BR112014001665 A2 BR 112014001665A2 BR 112014001665 A BR112014001665 A BR 112014001665A BR 112014001665 A BR112014001665 A BR 112014001665A BR 112014001665 A2 BR112014001665 A2 BR 112014001665A2
- Authority
- BR
- Brazil
- Prior art keywords
- plaz
- dihydroimidazo
- pyrimidin
- inhibitors
- compounds used
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
resumo “compostos de 2,3-di-hidroimidazo[1,2-c]pirimidin-5(1h)-ona utilizados como inibidores de lp-plaz” compostos de 2,3-di-hidroimidazo[1,2-c]pirimidin-5(ih)-ona que inibem lp-plaz, processos para a sua preparação, composições que os contêm e sua utiliza-ção no tratamento de doenças associadas com a atividade de lp-plaz, por exem-plo, aterosclerose, doença de alzheimer são divulgados.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011077697 | 2011-07-27 | ||
PCT/CN2012/000999 WO2013013503A1 (en) | 2011-07-27 | 2012-07-25 | 2,3-dihydroimidazo[1,2-c] pyrimidin-5(1h)-one compounds use as lp-pla2 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112014001665A2 true BR112014001665A2 (pt) | 2017-02-14 |
Family
ID=47600511
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014001665A BR112014001665A2 (pt) | 2011-07-27 | 2012-07-25 | compostos de 2,3-di-hidroimidazo[1,2-c]pirimidin-5(1h)-ona utilizados como inibidores de lp-plaz |
Country Status (9)
Country | Link |
---|---|
US (1) | US8975400B2 (pt) |
EP (1) | EP2739627A4 (pt) |
JP (1) | JP2014521611A (pt) |
KR (1) | KR20140059203A (pt) |
AU (1) | AU2012289492B2 (pt) |
BR (1) | BR112014001665A2 (pt) |
CA (1) | CA2842965A1 (pt) |
RU (1) | RU2014107484A (pt) |
WO (1) | WO2013013503A1 (pt) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR094563A1 (es) | 2013-01-25 | 2015-08-12 | Glaxosmithkline Ip Dev Ltd | Compuesto [5,6]bicíclico de imidazo pirimidona y composición farmacéutica que lo comprende |
UY35276A (es) * | 2013-01-25 | 2014-08-29 | Glaxosmithkline Ip Dev Ltd | Nuevos compuestos que inhiben la actividad de Lp-PLA2 |
CN103789401A (zh) * | 2014-02-14 | 2014-05-14 | 苏州莱泰生物科技有限公司 | 用于特异测定蛋白磷脂酶pla2g7活性的化合物 |
WO2016012916A1 (en) * | 2014-07-22 | 2016-01-28 | Glaxosmithkline Intellectual Property Development Limited | 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2 |
WO2016011930A1 (en) * | 2014-07-22 | 2016-01-28 | Glaxosmithkline Intellectual Property Development Limited | Compounds |
WO2016012917A1 (en) * | 2014-07-22 | 2016-01-28 | Glaxosmithkline Intellectual Property Development Limited | 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2 |
CN105777653A (zh) * | 2014-12-26 | 2016-07-20 | 中国科学院上海药物研究所 | 用作Lp-PLA2抑制剂的嘧啶酮类化合物及其药物组合物 |
CN106188063A (zh) * | 2015-05-08 | 2016-12-07 | 中国科学院上海药物研究所 | 用作Lp-PLA2抑制剂的双环类化合物、其制备方法及医药用途 |
AU2019395201A1 (en) | 2018-12-06 | 2021-05-20 | Daiichi Sankyo Company, Limited | Cycloalkane-1,3-diamine derivative |
CN112574221B (zh) * | 2019-09-30 | 2022-03-04 | 上海纽思克生物科技有限公司 | 四环嘧啶酮类化合物、其制备方法、其组合物和用途 |
CN114805389B (zh) | 2019-11-09 | 2023-08-29 | 上海赛默罗生物科技有限公司 | 三环二氢咪唑并嘧啶酮衍生物、其制备方法、药物组合物和用途 |
CN115304620A (zh) | 2021-05-07 | 2022-11-08 | 上海赛默罗生物科技有限公司 | 嘧啶酮衍生物、其制备方法、药物组合物和用途 |
WO2024027116A1 (en) * | 2022-08-04 | 2024-02-08 | 4B Technologies (Beijing) Co., Limited | Dihydroimidazo-pyrimidinone compounds as lp-pla2 inhibitors and use thereof |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9421816D0 (en) | 1994-10-29 | 1994-12-14 | Smithkline Beecham Plc | Novel compounds |
MX9704736A (es) | 1994-12-22 | 1997-10-31 | Smithkline Beecham Plc | Acetidin 2-onas sustituidas, procedimiento para prepararlas, uso de las mismas y composiciones que las contienen. |
CH690264A5 (fr) | 1995-06-30 | 2000-06-30 | Symphar Sa | Dérivés aminophosphonates substitués, leur procédé de préparation et leur utilisation pour la préparation de compositions pharmaceutiques. |
CZ422197A3 (cs) | 1995-07-01 | 1998-06-17 | Smithkline Beecham Plc | Azetidinonové deriváty, způsob jejich přípravy, meziprodukty tohoto postupu, farmaceutický prostředek obsahující tyto sloučeniny a použití těchto sloučenin jako léčiv |
WO1997012963A2 (en) | 1995-09-29 | 1997-04-10 | Smithkline Beecham Plc | A paf-acetylhydrolase and use in therapy |
EP0869943A1 (en) | 1995-12-08 | 1998-10-14 | Smithkline Beecham Plc | Monocyclic beta-lactame derivatives for treatment of atherosclerosis |
EP0865429A1 (en) | 1995-12-08 | 1998-09-23 | Smithkline Beecham Plc | Azetidinone compounds for the treatment of atherosclerosis |
GB9608649D0 (en) | 1996-04-26 | 1996-07-03 | Smithkline Beecham Plc | Novel compounds |
JP2000509049A (ja) | 1996-04-26 | 2000-07-18 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | アテローム性動脈硬化症の治療用アゼチジノン誘導体 |
GB9626616D0 (en) | 1996-12-20 | 1997-02-05 | Symphar Sa | Novel compounds |
GB9626536D0 (en) | 1996-12-20 | 1997-02-05 | Symphar Sa | Novel compounds |
GB9626615D0 (en) | 1996-12-20 | 1997-02-05 | Symphar Sa | Novel compounds |
ES2203988T3 (es) | 1997-11-06 | 2004-04-16 | Smithkline Beecham Plc | Compuestos de pirimidinona y composiciones farmaceuticas que los contienen. |
ATE251613T1 (de) | 1998-08-21 | 2003-10-15 | Smithkline Beecham Plc | Pyrimidinonderivate zur behandlung von atheroscleros |
GB9910079D0 (en) | 1999-05-01 | 1999-06-30 | Smithkline Beecham Plc | Novel compounds |
MXPA01011186A (es) | 1999-05-01 | 2002-08-12 | Smithkline Beecham Plc | Compuestos de pirimidinona. |
GB9910378D0 (en) | 1999-05-05 | 1999-06-30 | Smithkline Beecham Plc | Novel compounds |
JP3757703B2 (ja) | 1999-09-22 | 2006-03-22 | 凸版印刷株式会社 | 再封可能な開口維持部材付パウチ |
CA2400554C (en) | 2000-02-16 | 2009-04-07 | Smithkline Beecham P.L.C. | Pyrimidine-4-one derivatives as ldl-pla2 inhibitors |
GB0024808D0 (en) | 2000-10-10 | 2000-11-22 | Smithkline Beecham Plc | Novel compounds |
GB0024807D0 (en) | 2000-10-10 | 2000-11-22 | Smithkline Beecham Plc | Novel compounds |
GB0119795D0 (en) | 2001-08-14 | 2001-10-03 | Smithkline Beecham Plc | Novel process |
GB0119793D0 (en) | 2001-08-14 | 2001-10-03 | Smithkline Beecham Plc | Novel compounds |
GB0127141D0 (en) | 2001-11-10 | 2002-01-02 | Smithkline Beecham Plc | Novel compounds |
GB0127139D0 (en) | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Novel compounds |
GB0127143D0 (en) | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Novel compounds |
GB0127140D0 (en) | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Novel compounds |
GB0208280D0 (en) | 2002-04-10 | 2002-05-22 | Glaxo Group Ltd | Novel compounds |
GB0208279D0 (en) | 2002-04-10 | 2002-05-22 | Glaxo Group Ltd | Novel compounds |
WO2005003118A1 (de) | 2003-07-02 | 2005-01-13 | Bayer Healthcare Ag | Amid-substituierte 1,2,4-triazin-5 (2h)-one zur behandlung von chronisch inflammatorischen krankheiten |
DE102004061009A1 (de) | 2004-12-18 | 2006-06-22 | Bayer Healthcare Ag | Substituierte 1,2,4-Triazin-5(2H)-one |
DE102004061008A1 (de) | 2004-12-18 | 2006-06-22 | Bayer Healthcare Ag | 3-Arylalkyl- und 3-Heteroarylalkyl-substituierte 1,2,4-Triazin-5(2H)-one |
US20080090851A1 (en) | 2006-10-13 | 2008-04-17 | Colin Andrew Leach | Bicyclic Heteroaromatic Compounds |
WO2008048867A2 (en) | 2006-10-13 | 2008-04-24 | Glaxo Group Limited | Bicyclic heteroaromatic compounds |
US20080090852A1 (en) | 2006-10-13 | 2008-04-17 | Colin Andrew Leach | Bicyclic Heteroaromatic Compounds |
US7705005B2 (en) | 2006-10-13 | 2010-04-27 | Glaxo Group Limited | Bicyclic heteroaromatic compounds |
US20080279846A1 (en) | 2007-05-11 | 2008-11-13 | Thomas Jefferson University | Methods of treatment and prevention of neurodegenerative diseases and disorders |
US8962633B2 (en) | 2007-05-11 | 2015-02-24 | Thomas Jefferson University | Methods of treatment and prevention of metabolic bone diseases and disorders |
KR101563753B1 (ko) | 2007-05-11 | 2015-10-27 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 피부 궤양의 치료 방법 |
JP2011088847A (ja) * | 2009-10-21 | 2011-05-06 | Takeda Chem Ind Ltd | 三環性化合物およびその用途 |
-
2012
- 2012-07-25 WO PCT/CN2012/000999 patent/WO2013013503A1/en active Application Filing
- 2012-07-25 EP EP12818124.5A patent/EP2739627A4/en not_active Withdrawn
- 2012-07-25 AU AU2012289492A patent/AU2012289492B2/en not_active Expired - Fee Related
- 2012-07-25 CA CA2842965A patent/CA2842965A1/en not_active Abandoned
- 2012-07-25 US US14/234,680 patent/US8975400B2/en not_active Expired - Fee Related
- 2012-07-25 RU RU2014107484/04A patent/RU2014107484A/ru not_active Application Discontinuation
- 2012-07-25 KR KR1020147004711A patent/KR20140059203A/ko not_active Application Discontinuation
- 2012-07-25 BR BR112014001665A patent/BR112014001665A2/pt not_active IP Right Cessation
- 2012-07-25 JP JP2014521913A patent/JP2014521611A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2012289492A1 (en) | 2014-02-13 |
WO2013013503A1 (en) | 2013-01-31 |
CA2842965A1 (en) | 2013-01-31 |
EP2739627A1 (en) | 2014-06-11 |
RU2014107484A (ru) | 2015-09-10 |
KR20140059203A (ko) | 2014-05-15 |
EP2739627A4 (en) | 2015-01-21 |
AU2012289492B2 (en) | 2016-02-04 |
US8975400B2 (en) | 2015-03-10 |
JP2014521611A (ja) | 2014-08-28 |
US20140179715A1 (en) | 2014-06-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112014001665A2 (pt) | compostos de 2,3-di-hidroimidazo[1,2-c]pirimidin-5(1h)-ona utilizados como inibidores de lp-plaz | |
DOP2022000096A (es) | Formas cristalinas de un inhibidor de tirosina quinasa de bruton | |
CO2017011851A2 (es) | Compuestos novedosos | |
PH12015501586A1 (en) | 2,3-dihydroimidazol[1,2-c]pyrimidin-5(1h)-one based lipoprotein-associated phospholipase a2 (lp-pla2) inhibitors | |
BR112014001634A2 (pt) | compostos bicíclicos de pirimidona | |
CL2016001895A1 (es) | Compuestos | |
MX336381B (es) | Boronatos como inhibidores de arginasa. | |
CL2014001752A1 (es) | Compuestos biciclicos sustituidos; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades tales como cancer, alzheimer, sida, entre otras. | |
PH12015500758A1 (en) | Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases | |
CL2015003801A1 (es) | Formulaciones de anticuerpos y metodos | |
BR112012020693A2 (pt) | derivados de ciclobutano e metilciclobutano como inibidores de janus quinase | |
BR112015010663A8 (pt) | formas de dosagem oral de liberação sustentada, e uso de ruxolitinib ou de sal farmaceuticamente aceitável do mesmo | |
DOP2014000062A (es) | Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas | |
BR112015021888A8 (pt) | inibidores de dna-pk, seus usos e composição farmacêutica | |
DOP2014000043A (es) | Pirimidinas anilladas sustituidas y uso de las mismas | |
MX355758B (es) | Analogos constreñidos en el anillo como inhibidores de arginasa. | |
UY33616A (es) | Compuestos con estructura de imidazotriazinona | |
UY33766A (es) | COMPUESTOS CON ESTRUCTURA DE PIRIMIDINONA PARA USO EN EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR Lp-PLA2 | |
AR101261A1 (es) | Compuesto de tetrahidropirrolo[1,2:3,4]imidazo[1,2-c]pirimidin-1(6h)-ona y composición farmacéutica que lo comprende | |
BR112013025777A2 (pt) | imidazopiridazinas como inibidores da quinase akt | |
EA201300871A1 (ru) | ПРОИЗВОДНЫЕ (1,2,4)ТРИАЗОЛО[4,3-a]ХИНОКСАЛИНА В КАЧЕСТВЕ ИНГИБИТОРОВ ФОСФОДИЭСТЕРАЗ | |
BR112014009006B8 (pt) | Compostos heterocíclicos e métodos de uso dos mesmos | |
CL2013001482A1 (es) | Compuestos derivados de 3-metil-7-oxo-4-tia-1-aza-biciclo[3.2.0]heptano para utilizarse en la inhibicion de beta-lactamasas producidas por bacterias y restaurar/potenciar la actividad de antibioticos; y composicion farmaceutica que los comprende. | |
CL2013003056A1 (es) | Compuestos derivados de (fenil o piridin)-etinil-(piridin o pirimidin) sustituido; composición farmacéutica que los comprende; proceso de preparación de esto; y su uso en el tratamiento de la esquizofrenia o enfermedades cognitivas. | |
BR112015017397A2 (pt) | compostos pirimidona bicíclica como inibidores de lp-pla2 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application fees: dismissal - article 86 of industrial property law | ||
B08K | Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87) |